A Short-term Predictive Model for Disease Progression in Acute-on-chronic Liver Failure: Integrating Spectral CT Extracellular Liver Volume and Clinical Characteristics

Overview

Journal BMC Med Imaging

Publisher Biomed Central

Specialty Radiology

Date 2025 Mar 3

PMID 40033256

Authors

Yuan Xu

Fukai Li

Bo Liu

Tiezhu Ren

Jiachen Sun

Yufeng Li

Hong Liu

Jianli Liu

Junlin Zhou

Affiliations

Soon will be listed here.

Abstract

Background: Acute-on-chronic liver failure (ACLF) is a life-threatening hepatic syndrome. Therefore, this study aimed to develop a comprehensive model combining extracellular liver volume derived from spectral CT (ECV) and sarcopenia, for the early prediction of short-term (90-day) disease progression in ACLF.

Materials And Methods: A retrospective cohort of 126 ACLF patients who underwent hepatic spectral CT scans was included. According to the Asia-Pacific Association for the Study of the Liver (APASL) criteria, patients were divided into the progression group (n = 70) and the stable group (n = 56). ECV was measured on the equilibrium period (EP) images of spectral CT, and L3-SMI was measured on unenhanced CT images, with sarcopenia assessed. A comprehensive model was developed by combining independent predictors. Model performance was evaluated using receiver operating characteristic (ROC) curve analysis, calibration curves, and decision curve analysis (DCA).

Results: In the univariate analysis, BMI, WBC, PLT, PTA, L3-SMI, IC-EP, Z-EP, K-EP, NIC-EP, ECV, and Sarcopenia demonstrated associations with disease progression status at 90 days in ACLF patients. In multivariate logistic regression, white blood cell count (WBC) (OR = 1.19, 95% CI: 1.02-1.40; P = 0.026), ECV (OR = 1.27, 95% CI: 1.15-1.40; P < 0.001), sarcopenia (OR = 4.15, 95% CI: 1.43-12.01; P = 0.009), MELD-Na score (OR = 1.06, 95%CI: 1.01-1.13;P = 0.042), and CLIF-SOFA score (OR = 1.37, 95%CI:1.15-1.64; P<0.001) emerged as independent risk factors for ACLF progression. The combined model exhibited superior predictive performance (AUCs = 0.910, sensitivity = 80.4%, specificity = 90.0%, PPV = 0.865, NPV = 0.851) compared to CLIF-SOFA, MELD-Na, MELD and CTP scores(both P < 0.001). Calibration curves and DCA confirmed the high clinical utility of the combined model.

Conclusions: Patients without sarcopenia and/or with a lower ECV have a better prognosis, and the integration of WBC, ECV, Sarcopenia, CLIF-SOFA and MELD-Na scores in a composite model offers a concise and effective tool for predicting disease progression in ACLF patients.

Trial Registration: Not Applicable.

References

Zhou D, Zhang D, Zeng C, Zhang L, Gao X, Wang X . Impact of sarcopenia on the survival of patients undergoing liver transplantation for decompensated liver cirrhosis. J Cachexia Sarcopenia Muscle. 2023; 14(6):2602-2612. PMC: 10751414. DOI: 10.1002/jcsm.13334. View

Koya S, Kawaguchi T, Hashida R, Hirota K, Bekki M, Goto E . Effects of in-hospital exercise on sarcopenia in hepatoma patients who underwent transcatheter arterial chemoembolization. J Gastroenterol Hepatol. 2018; 34(3):580-588. DOI: 10.1111/jgh.14538. View

Wu Y, Li M, Zhang Y, Gao R, Su Y, Zhou Y . The sarcopenia index is an effective predictor for malnutrition in patients with liver cirrhosis. Nutr Diet. 2022; 79(5):563-571. DOI: 10.1111/1747-0080.12738. View

Bayani A, Hosseini A, Asadi F, Hatami B, Kavousi K, Aria M . Identifying predictors of varices grading in patients with cirrhosis using ensemble learning. Clin Chem Lab Med. 2022; 60(12):1938-1945. DOI: 10.1515/cclm-2022-0508. View

Marasco G, Dajti E, Ravaioli F, Brocchi S, Rossini B, Alemanni L . Clinical impact of sarcopenia assessment in patients with liver cirrhosis. Expert Rev Gastroenterol Hepatol. 2020; 15(4):377-388. DOI: 10.1080/17474124.2021.1848542. View

Liu C, Shen Z, Ma H, Wang X, Wang X, Liu K . Gd-BOPTA-enhanced hepatobiliary phase MR imaging can predict the prognosis of patients with acute-on-chronic liver failure. Eur Radiol. 2022; 32(5):3006-3015. DOI: 10.1007/s00330-021-08440-5. View

Verma N, Dhiman R, Singh V, Duseja A, Taneja S, Choudhury A . Comparative accuracy of prognostic models for short-term mortality in acute-on-chronic liver failure patients: CAP-ACLF. Hepatol Int. 2021; 15(3):753-765. DOI: 10.1007/s12072-021-10175-w. View

Moreau R . The Pathogenesis of ACLF: The Inflammatory Response and Immune Function. Semin Liver Dis. 2016; 36(2):133-40. DOI: 10.1055/s-0036-1583199. View

Kang S, Jeong W, Baik S, Cha S, Kim M . Impact of sarcopenia on prognostic value of cirrhosis: going beyond the hepatic venous pressure gradient and MELD score. J Cachexia Sarcopenia Muscle. 2018; 9(5):860-870. PMC: 6204582. DOI: 10.1002/jcsm.12333. View

10.

Nishikawa H, Shiraki M, Hiramatsu A, Moriya K, Hino K, Nishiguchi S . Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol Res. 2016; 46(10):951-63. DOI: 10.1111/hepr.12774. View

11.

Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J . Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013; 144(7):1426-37, 1437.e1-9. DOI: 10.1053/j.gastro.2013.02.042. View

12.

Liu L, Zhang Y, Nie Y, Zhu X . Assessing the Prediction Effect of Various Prognosis Model for 28-Day Mortality in Acute-on-Chronic Liver Failure Patients. Risk Manag Healthc Policy. 2021; 13:3155-3163. PMC: 7778450. DOI: 10.2147/RMHP.S281999. View

13.

Cai X, Liu M, Xu X, Zhang S, Huang R, Wang P . Cardiovascular effects of weight loss in old adults with overweight/obesity according to change in skeletal muscle mass. J Cachexia Sarcopenia Muscle. 2023; 15(1):342-351. PMC: 10834329. DOI: 10.1002/jcsm.13409. View

13.

Xu Y, Li Y, Li S, Xue S, Liu J . Dual-energy CT quantification of extracellular liver volume predicts short-term disease progression in patients with hepatitis B liver cirrhosis-acute decompensation. Insights Imaging. 2023; 14(1):51. PMC: 10050608. DOI: 10.1186/s13244-023-01393-x. View

14.

Sarin S, Choudhury A, Sharma M, Maiwall R, Al Mahtab M, Rahman S . Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019; 13(4):353-390. PMC: 6728300. DOI: 10.1007/s12072-019-09946-3. View

15.

Zeng F, Jiang W, Chang X, Yang F, Luo X, Liu R . Sarcopenia is associated with short- and long-term mortality in patients with acute-on-chronic liver failure. J Cachexia Sarcopenia Muscle. 2024; 15(4):1473-1482. PMC: 11294047. DOI: 10.1002/jcsm.13501. View

16.

Hernaez R, Liu Y, Kramer J, Rana A, El-Serag H, Kanwal F . Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure. J Hepatol. 2020; 73(6):1425-1433. PMC: 10424237. DOI: 10.1016/j.jhep.2020.06.005. View

17.

Jalan R, Gustot T, Fernandez J, Bernal W . 'Equity' and 'Justice' for patients with acute-on chronic liver failure: A call to action. J Hepatol. 2021; 75(5):1228-1235. DOI: 10.1016/j.jhep.2021.06.017. View

18.

Gustot T, Fernandez J, Garcia E, Morando F, Caraceni P, Alessandria C . Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology. 2015; 62(1):243-52. DOI: 10.1002/hep.27849. View

19.

Lee S, Song M, Kim S, Park M . Comparing various scoring system for predicting overall survival according to treatment modalities in hepatocellular carcinoma focused on Platelet-albumin-bilirubin (PALBI) and albumin-bilirubin (ALBI) grade: A nationwide cohort study. PLoS One. 2019; 14(5):e0216173. PMC: 6497276. DOI: 10.1371/journal.pone.0216173. View